Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of AD 923 (sublingual fentanyl) for breakthrough cancer pain
2007-000559-32Phase 3Terminated
- Sponsor
- Nxera Pharma
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of AD-923 in breakthrough cancer pain (BTcP) and cancer pain, sponsored by Nxera Pharma. Primary endpoint: Safety and tolerability of AD 923. Started Oct 2007; status: terminated.
02
Drugs
AD-923
03
Conditions
breakthrough cancer pain (BTcP)cancer pain
Beyond the preview
Go deeper on 2007-000559-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000559-32.